The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ventive secures c.£900,000 investment

6 Nov 2023 07:00

RNS Number : 4115S
NetScientific PLC
06 November 2023
 

For release: 07.00, 6 November 2023

 

 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Heat pump specialist Ventive secures c.£900,000 investment

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that its portfolio company Ventive has successfully closed a c.£900,000 investment ("Investment").

The Investment included £316,000 from existing shareholders and the conversion of two existing convertible loans (and interest thereon) valued at c.£600,000. This is the first closing as part of Ventive's proposed £1 million to £1.5 million investment programme, with further new investment anticipated prior to 30 April 2024 in one or more additional closings.

This additional funding is complemented by ongoing non-dilutive funding from, amongst other grants awarded, a £1.5 million BEIS grant secured in 2022, as well as a recently awarded £100,000 UK Government grant focused on 'net zero HVAC' systems.

The Investment was led and syndicated by EMV Capital, the Company's wholly owned venture capital and corporate finance firm. It follows the initial investment led and syndicated by EMV Capital that was announced (via RNS Reach) on 20 October 2022, where EMV Capital secured an initial c.16% stake in partial settlement of its fees. Since that initial investment, the value creation team of EMV Capital has worked closely with Ventive to stabilise and develop its business plan and product range.

The proceeds of the Investment will support the completion of the design and test phase and factory build for Ventive's modular heat pumps, further enhancements to its passive air ventilation product range, and build-up of its marketing and sales capacity to drive sales of its existing product range. The Ventive balance sheet is also streamlined following the conversion of the convertible loans.

Following completion of the Investment, the total equity holding of the NetScientific group in Ventive is 11.0% on a fully diluted basis, which includes the partial settlement of its corporate finance fees relating to the Investment. This holding equates to a post-investment fair value of £893,000, a substantial increase of 1,617% from the £52,000 reported as at 31 December 2022. In addition, following the introduction of investors to Ventive by EMV Capital under its capital efficient model, NetScientific's capital under advisory with Ventive is now 23.8% of the fully diluted share capital. 

Ventive designs and manufactures intelligent heating and ventilation solutions to make buildings healthy, comfortable, efficient, and affordable. Its products address two high priority markets segments: air quality and sustainable heating.

Ventive's passive air ventilation system has been delivered to over 30 schools and five leisure centres, achieving excellent air quality results. Its novel heat pump product, which is in advanced stages of development, is a comprehensive solution for residential applications, with a unique modular design and a novel thermal store. Momentum for the business is underpinned by significant regulatory changes, increasing energy prices, and climate change policies.

Rob Morrison, Managing Director of Ventive, said:

"This investment is a strong endorsement of our work, and recognition of Ventive as a pioneer in the design of naturally intelligent ventilation systems to deliver fresh air at minimal energy cost. Since heat pumps are powered by electricity, a comparatively easy source of energy to decarbonise, they can play a prominent role in bringing down the environmental footprint of homes and other buildings.

"EMV Capital has provided invaluable support to our fundraising efforts and growth strategy planning, and we are grateful to our shareholders for their continued support in a tough macro-economic climate."

Ed Hooper, Executive Director of NetScientific and Investment Director at Ventive, added:

"We are pleased to see Ventive close out the first tranche of this important fundraising programme, which includes both fresh investment and the conversion of existing convertible loans. This transaction again demonstrates the strength of our capital efficient investment model and the successful execution of our strategy to increase the net asset value and fair value of our business by progressing cohort portfolio companies through value creation stages, obtaining third party investment, and providing proactive portfolio management.

"We believe that this fundraising positions Ventive well for further growth and we look forward to continuing to work closely with Ventive in this rapidly growing high-impact market segment."

 

 

The person responsible for arranging the release of this announcement on behalf of the Company is Edward Hooper, General Counsel and Executive Director of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

-Ends-

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

 

Emma Earl / Freddy Crossley / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Belvedere Communications

John West / Llew Angus / Lily Pearce

 

+44 (0)20 7653 8702

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

About Ventive

Ventive designs and manufactures innovative intelligent building service systems in the UK, with an aim to create comfort without costing the Earth. From ventilation to heating and cooling, its ambitious team has already commercialised a few technologies and is well positioned to address the complexities of the Energy Transition with its new range of all-in-one home energy systems. Ventive has the ambition to provide a healthy, comfortable and safe indoor environment intelligently and at a reasonable cost, also opening the opportunity to help demand for energy management on an aggregated scale.

Ventive was founded by serial entrepreneur and architect Tom Lipinski with a vision to improve the comfort and sustainability of residential built environment.

https://ventive.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURFLFEFLELEIIV
Date   Source Headline
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC
4th Jan 20199:13 amRNSForm 8.5 - NetScientific PLC
31st Dec 20189:36 amRNSForm 8.5 - NetScientific PLC
24th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
21st Dec 201811:04 amRNSForm 8.5 - NetScientific PLC
20th Dec 20184:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.